Gilbert, P. B., Montefiori, D. C., McDermott, A., Fong, Y., Benkeser, D. C., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., Castellino, F., Flach, B., Lin, B. C., O’Connell, S., McDanal, C., Eaton, A., Sarzotti-Kelsoe, M., Lu, Y., Yu, C., … Teams, U. S. G. (USG)/CoVPN B. (2021). Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. MedRxiv, 2021.08.09.21261290. https://doi.org/10.1101/2021.08.09.21261290

Willsher, K. (2021, October 11). French study of over 22m people finds vaccines cut severe Covid risk by 90%. The Guardian. https://www.theguardian.com/world/2021/oct/11/french-study-vaccines-cut-covid-deaths

Mulot, M., Segalas, C., Leyrat, C., & Besançon, L. (2021). Vaccination rates and COVID-19 cases: A commentary of “Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States.” OSF Preprints. https://doi.org/10.31219/osf.io/72abp

Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., Brengel-Pesce, K., Yaugel-Novoa, M., Denolly, S., Boson, B., Bourlet, T., Bal, A., Valette, M., Andrieu, T., Lina, B., … Trouillet-Assant, S. (2021). Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. Nature, 1–9. https://doi.org/10.1038/s41586-021-04120-y

Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., Martinez, D. R., Giffin, T., Hope, D., Patel, S., Sellers, D., Sanborn, O., Barrett, J., Liu, X., Cole, A. C., … Barouch, D. H. (2021). Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine. Nature, 1–8. https://doi.org/10.1038/s41586-021-04231-6

Iketani, S., Liu, L., Guo, Y., Liu, L., Huang, Y., Wang, M., Luo, Y., Yu, J., Yin, M. T., Sobieszczyk, M. E., Huang, Y., Wang, H. H., Sheng, Z., & Ho, D. D. (2022). Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages (p. 2022.02.07.479306). bioRxiv. https://doi.org/10.1101/2022.02.07.479306

Zimmer, C. (2021, September 21). An extra J. & J. shot substantially boosts protection against Covid, the company reports. The New York Times. https://www.nytimes.com/2021/09/21/health/johnson-and-johnson-shot.html

Dowdy, D. (2021, September 21). On the J&J booster news, keep in mind: 1. Median follow-up since 2nd dose was just 36 days, 2. Efficacy vs moderate COVID was 75% globally, and 3. Total number of cases in the US was 15. Please don’t take this to mean that a 2nd dose provides long-term increase in protection. Https://t.co/RnqDNBmwuD [Tweet]. @davidwdowdy. https://twitter.com/davidwdowdy/status/1440323242942554122

DemTech | COVID-19 Misinformation Newsletter 24 August 2021. (2021, August 24). https://demtech.oii.ox.ac.uk/covid-19-misinformation-newsletter-24-august-2021/#continue

Krause, P. R., Fleming, T. R., Peto, R., Longini, I. M., Figueroa, J. P., Sterne, J. A. C., Cravioto, A., Rees, H., Higgins, J. P. T., Boutron, I., Pan, H., Gruber, M. F., Arora, N., Kazi, F., Gaspar, R., Swaminathan, S., Ryan, M. J., & Henao-Restrepo, A.-M. (2021). Considerations in boosting COVID-19 vaccine immune responses. The Lancet, 4. https://doi.org/10.1016/S0140-6736(21)02046-8

Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., Biber, A., Nemet, I., Kliker, L., Joseph, G., Doolman, R., Mendelson, E., Freedman, L. S., Harats, D., Kreiss, Y., & Lustig, Y. (2022). 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC (p. 2022.02.15.22270948). medRxiv. https://doi.org/10.1101/2022.02.15.22270948

Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Gupta, R. K. (2022). Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature, 1–1. https://doi.org/10.1038/s41586-022-04474-x

Ozernov-Palchik, O., Olson, H., Arechiga, X., Kentala, H., Solorio-Fielder1, J. L., Wang, K. L., Torres, Y. C., Gardino, N. D., Dieffenbach, J. R., & Gabrieli, J. (2021). Implementing Remote Developmental Research: A Case Study of an RCT Language Intervention During COVID-19. PsyArXiv. https://doi.org/10.31234/osf.io/k9632

We could read this together as a group, and do some thinking prior to the discussion, or at least even read what other people are thinking.

James Ward on Twitter. (n.d.). Twitter. Retrieved April 21, 2022, from https://twitter.com/JamesWard73/status/1470680953643319305

Morris, J. (2021, August 17). Israeli data: How can efficacy vs. severe disease be strong when 60% of hospitalized are vaccinated? Covid Data Science. https://www.covid-datascience.com/post/israeli-data-how-can-efficacy-vs-severe-disease-be-strong-when-60-of-hospitalized-are-vaccinated

Carl T. Bergstrom. (2021, August 18). 1. There has been lots of talk about recent data from Israel that seem to suggest a decline in vaccine efficacy against severe disease due to Delta, waning protection, or both. This may have even been a motivation for Biden’s announcement that the US would be adopting boosters. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1427767356600688646

Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

Dr Ellie Murray, ScD. (2021, July 6). Also, see👇🏼 [Tweet]. @EpiEllie. https://twitter.com/EpiEllie/status/1412249702460968967

(((Howard Forman))). (2021, June 28). There are few more compelling graphics to demonstrate how effective vaccines are: 80+% reduction in hospital admissions for the group most vaccinated. <40% reduction in admissions for the group least likely to be vaccinated. [Tweet]. @thehowie. https://twitter.com/thehowie/status/1409492774009847810

Prof. Christina Pagel. (2021, May 23). LONG THREAD on B.1.617.2 & latest PHE data covering: 1) latest tech report on B.1.617.2 (aka ‘India’ variant) 2) vaccine efficacy against B.1.617.2 3) consequences for roadmap 4) avoidability... Or not. [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1396574267349872644

Marc Lipsitch. (2021, July 20). At the risk of boiling down too much and certainly losing some detail, one way to summarize this wonderful thread is that when we think about vaccine effectiveness, we should think of 4 key variables: 1 which vaccine, 2 age of the person, 3 how long after vax, 4 vs what outcome. [Tweet]. @mlipsitch. https://twitter.com/mlipsitch/status/1417595538632060931

Just 1 per cent of eligible Canberrans are unvaccinated as the capital becomes one of world’s most-vaccinated cities. (2021, December 30). ABC News. https://www.abc.net.au/news/2021-12-31/covid-canberras-unvaccinated-1-per-cent-in-a-highly-vaxxed-city/100642468

CDC. (2022, February 4). A new @CDCMMWR study shows that people who reported always wearing masks or respirators in indoor public settings in California were less likely to test positive for #COVID19 compared with those who reported not wearing a face covering. Learn more. Http://bit.ly/MMWR7106 https://t.co/6UJ9cs60NK [Tweet]. @CDCgov. https://twitter.com/CDCgov/status/1489675180242870278

ReconfigBehSci. (2021, July 19). this is how the failure to understand what efficacy means and how it relates to outcomes will be seized on over and over again. Cookie cutter fallacies require cookie cutter clarification by machine tools to be combatted effectively (at least at current levels of moderation) [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1417164191664730112

Eran Segal. (2021, August 17). Israel data showing the decay of vaccine efficacy over time. Y-axis is cases per 1000 from July 7 to Aug 10, for unvaccinated, and for people vaccinated at different times Cases are higher in those vaxed earlier Despite world-data caveats, this seems quite compelling https://t.co/5aNz48AC8F [Tweet]. @segal_eran. https://twitter.com/segal_eran/status/1427696623988117505

CNN, A. S. (n.d.). Pfizer begins Phase 2 and 3 trial of Covid-19 antiviral Paxlovid in children ages 6 to 17. CNN. Retrieved 22 March 2022, from https://www.cnn.com/2022/03/09/health/pfizer-paxlovid-pediatric-trial/index.html

Yang, M. (2022, February 28). Pfizer vaccine significantly less effective in children ages five to 11, study shows. The Guardian. https://www.theguardian.com/society/2022/feb/28/pfizer-vaccine-less-effective-children-ages-five-to-11-data

Mahase, E. (2022). Covid-19: Sanofi and GSK to seek regulatory authorisation for protein based vaccine. BMJ, 376, o526. https://doi.org/10.1136/bmj.o526

Mancini, D. P., & Smyth, J. (2022, February 16). Merck struggles to win European approval for Covid-19 antiviral pill. Financial Times. https://www.ft.com/content/2cf0b6cc-b07b-4ff9-a833-42eb1798a576

Academics: Viral Evolution Scenarios, 10 February 2022. (n.d.). GOV.UK. Retrieved February 14, 2022, from https://www.gov.uk/government/publications/academics-viral-evolution-scenarios-10-february-2022

Mahase, E. (2022). Covid-19: What do we know about omicron sublineages? BMJ, 376, o358. https://doi.org/10.1136/bmj.o358

American Medical Association (AMA). (2021, December 6). Peter Hotez, MD, PhD, on the omicron variant and Delta winter surge | COVID-19 Update for Dec. 6, 20. https://www.youtube.com/watch?v=WnfpC1_N2Mg

Afkhami, S., D’Agostino, M. R., Zhang, A., Stacey, H. D., Marzok, A., Kang, A., Singh, R., Bavananthasivam, J., Ye, G., Luo, X., Wang, F., Ang, J. C., Zganiacz, A., Sankar, U., Kazhdan, N., Koenig, J. F. E., Phelps, A., Gameiro, S. F., Tang, S., … Xing, Z. (2022). Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, S0092867422001453. https://doi.org/10.1016/j.cell.2022.02.005

Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., Vézina, D., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Fournier, É., Guilbault, A., Delisle, B., Levade, I., … Finzi, A. (2022). SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses. Cell Reports, 0(0). https://doi.org/10.1016/j.celrep.2022.110429

PaedsHaemDoc. (2022, January 9). Had the misfortune (via @fatemperor) to come across Dr Paul Alexander -apparently credentialed yet in single blog post demonstrates perfectly either a disconnect from rational thought or deliberate misinformation spreading of the #masspsychosis of the anti-Vax crew let’s examine https://t.co/Ctd49cb1qK [Tweet]. @dr_barrett. https://twitter.com/dr_barrett/status/1479986071832248322

Mahase, E. (2022). Omicron sub-lineage BA.2 may have “substantial growth advantage,” UKHSA reports. BMJ, 376, o263. https://doi.org/10.1136/bmj.o263

Devlin, H., & correspondent, H. D. S. (2022, February 3). Novavax Covid vaccine approved for use in over-18s in UK. The Guardian. https://www.theguardian.com/society/2022/feb/03/novavax-covid-vaccine-approved-for-use-in-over-18s-in-uk

ReconfigBehSci on Twitter: “RT @AliHMokdad: Vaccine effectiveness against BA.1 and BA.2. After 2 doses it was 9% (7-10%) and 13% (-26-40%) respectively for BA.1 and BA…” / Twitter. (n.d.). Retrieved January 30, 2022, from https://twitter.com/SciBeh/status/1487123660771106821

Which can lead to an assessment of pedagogical efficacy. It's funny, to me, that those who complain about "grade inflation" (typically admins) rarely entertain the notion that grades could be higher than usual if the course went well. The situation is quite different in "L&D" (Learning and Development, typically for training and professional development in an organizational context). "Oh, great! We were able to get everyone to reach the standard for this competency! Must mean that we've done something right in our Instructional Design!"

Yang, M. (2022, January 14). ‘Menace to public health’: 270 doctors criticize Spotify over Joe Rogan’s podcast. The Guardian. https://www.theguardian.com/technology/2022/jan/14/spotify-joe-rogan-podcast-open-letter

Augustin, E. (2022, January 5). Cuba’s vaccine success story sails past mark set by rich world’s Covid efforts. The Guardian. https://www.theguardian.com/world/2022/jan/05/cuba-coronavirus-covid-vaccines-success-story

Allyson Pollock. (2022, January 2). I am told that masks obey the law of physics! How does theory translate into practice? How often do you touch mask, wash it, shove it in your pocket? If you sneeze/cough do you a) take mask off, use a handkerchief, wash hands b) keep mask on -if so where does the snot go? [Tweet]. @AllysonPollock. https://twitter.com/AllysonPollock/status/1477737957054365696

Calgary Herald. (n.d.). Calgaryherald. Retrieved December 21, 2021, from https://calgaryherald.com/news/local-news/anti-covid-vaccine-dad-loses-battle-with-ex-wife-over-whether-to-get-their-children-inoculated

227 B.C. chiropractors threaten to sue regulatory college if vaccines ordered. (n.d.). Vancouversun. Retrieved December 17, 2021, from https://vancouversun.com/news/local-news/227-b-c-chiropractors-threaten-to-sue-regulatory-college-if-vaccines-ordered

Vaccination among the pregnant lagging despite growing evidence of safety and efficacy. (2021, December 10). Healthy Debate. https://healthydebate.ca/2021/12/topic/vaccination-pregnant-safe-efficacy/

‘It’s misinformation at worst.’ Weak health studies can do more harm than good, scientists say. (n.d.). Retrieved December 13, 2021, from https://www.science.org/content/article/it-s-misinformation-worst-weak-health-studies-can-do-more-harm-good-scientists-say

Ortiz, J. R., & Neuzil, K. M. (2021). The value of vaccine programme impact monitoring during the COVID-19 pandemic. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)02322-9

THL recommends coronavirus vaccinations for at-risk children aged 5 to 11 years, for the entire age group require more information on safety—Press release—THL. (n.d.). Finnish Institute for Health and Welfare (THL), Finland. Retrieved December 6, 2021, from https://thl.fi/en/web/thlfi-en/-/thl-recommends-coronavirus-vaccinations-for-at-risk-children-aged-5-to-11-years-for-the-entire-age-group-require-more-information-on-safety?redirect=%2Fen%2Fweb%2Fthlfi-en%2Fwhats-new

Sridhar, D. (2021, November 28). How bad will the Omicron Covid variant be in Britain? Three things will tell us. The Guardian. https://www.theguardian.com/commentisfree/2021/nov/28/omicron-covid-variant-britain-southern-africa

Cause for optimism on Omicron: Our immune systems aren’t blank slates. (2021, December 1). STAT. https://www.statnews.com/2021/12/01/a-reason-for-optimism-on-omicron-our-immune-systems-are-not-blank-slates/

COVID-19: Most Omicron cases are “mild” and there’s no evidence to suggest vaccines may be less effective against the variant, says WHO official. (n.d.). Sky News. Retrieved December 2, 2021, from https://news.sky.com/story/covid-19-most-omicron-cases-are-mild-and-theres-no-evidence-to-suggest-vaccines-may-be-less-effective-against-the-variant-says-who-12483729

FDA authorizes Pfizer-BioNTech, Moderna boosters for all adults. (2021). Washington Post. Retrieved November 22, 2021, from https://www.washingtonpost.com/health/2021/11/19/fda-clears-pfizer-biontech-moderna-booster-shots-all-adults/

COVID-19 vaccine surveillance report—Week 47. (n.d.). 46.

Wheatley, A. K., & Juno, J. A. (2021). COVID-19 vaccines in the age of the delta variant. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00688-5

Reardon, S. (2021). Cuba’s bet on home-grown COVID vaccines is paying off. Nature. https://doi.org/10.1038/d41586-021-03470-x

Covid: US approves Pfizer vaccine for children over five. (2021, November 3). BBC News. https://www.bbc.com/news/world-us-canada-59044853

Walter, E. B., Talaat, K. R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G. C., Barnett, E. D., Muñoz, F. M., Maldonado, Y., Pahud, B. A., Domachowske, J. B., Simões, E. A. F., Sarwar, U. N., Kitchin, N., Cunliffe, L., Rojo, P., Kuchar, E., Rämet, M., Munjal, I., … Gruber, W. C. (2021). Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, NEJMoa2116298. https://doi.org/10.1056/NEJMoa2116298

Otte, J. (2021, November 11). ‘No jab, no job’: Care home workers in England on the Covid vaccine mandate. The Guardian. https://www.theguardian.com/society/2021/nov/11/england-care-home-workers-on-mandatory-covid-vaccines

Gurdasani, D., Bhatt, S., Costello, A., Denaxas, S., Flaxman, S., Greenhalgh, T., Griffin, S., Hyde, Z., Katzourakis, A., McKee, M., Michie, S., Ratmann, O., Reicher, S., Scally, G., Tomlinson, C., Yates, C., Ziauddeen, H., & Pagel, C. (2021). Vaccinating adolescents against SARS-CoV-2 in England: A risk–benefit analysis. Journal of the Royal Society of Medicine, 01410768211052589. https://doi.org/10.1177/01410768211052589

Prof Peter Hotez MD PhD. (2021, October 30). Many thanks @FWhitfield for hosting me this Saturday AM @CNN In case it’s helpful, I’ve prepared an informal ‘fact sheet’ on COVID in children and COVID vaccines in 5-11 age group. Highlights attached...feel free to RT or repurpose the information [Tweet]. @PeterHotez. https://twitter.com/PeterHotez/status/1454489603013062656

Kennedy-Shaffer, L., Kahn, R., & Lipsitch, M. (2021). Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load. Epidemiology (Cambridge, Mass.), 32(6), 820–828. https://doi.org/10.1097/EDE.0000000000001415

Follmann, D., & Fay, M. (2021). Vaccine Efficacy at a Point in Time (p. 2021.02.04.21251133). https://doi.org/10.1101/2021.02.04.21251133

Measuring vaccine efficacy from population data. (n.d.). The Centre for Evidence-Based Medicine. Retrieved 29 October 2021, from https://www.cebm.net/covid-19/measuring-vaccine-efficacy-from-population-data/

For Teens with Obesity, COVID Vaccines Save Lives. (2021, October 21). ConscienHealth. https://conscienhealth.org/2021/10/for-teens-with-obesity-covid-vaccines-save-lives/

Rono, E. K. (2021). Covid-19 genomic analysis reveals clusters of emerging sublineages within the delta variant [Preprint]. Genomics. https://doi.org/10.1101/2021.10.08.463334

Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., Pandey, R., Brown, J., Zhou, J., Goonawardane, N., Mishra, S., Whittaker, C., Mellan, T., Marwal, R., Datta, M., … Gupta, R. K. (2021). SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 1–6. https://doi.org/10.1038/s41586-021-03944-y

Hilda Bastian, PhD on Twitter. (n.d.). Twitter. Retrieved 10 October 2021, from https://twitter.com/hildabast/status/1440714908924923904

‘A bit of a mystery’: Why hospital admissions for Covid in England are going down | Coronavirus | The Guardian. (n.d.). Retrieved 8 October 2021, from https://www.theguardian.com/world/2021/sep/24/a-bit-of-a-mistery-why-england-covid-cases-are-going-down-despite-ease-of-restrictions

Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest—Clover Biopharmaceuticals. (n.d.). Retrieved 4 October 2021, from https://www.cloverbiopharma.com/news/83.html

Palm, R., Bolsen, T., & Kingsland, J. T. (2021). The Effect of Frames on COVID-19 Vaccine Resistance. Frontiers in Political Science, 3, 661257. https://doi.org/10.3389/fpos.2021.661257

Kupferschmidt, K., VogelMar. 27, G., 2021, & Am, 10:20. (2021, March 27). A rare clotting disorder may cloud the world’s hopes for AstraZeneca’s COVID-19 vaccine. Science | AAAS. https://www.sciencemag.org/news/2021/03/rare-clotting-disorder-may-cloud-worlds-hopes-astrazenecas-covid-19-vaccine

Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E. A., Collins, A. M., Cox, T., Darton, T. C., Dold, C., Douglas, A. D., Duncan, C. J. A., Ewer, K. J., Flaxman, A. L., … Pollard, A. J. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)00628-0

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0/fulltext

Bastian, H. (2021, June 24). The mRNA Vaccines Are Extraordinary, but Novavax Is Even Better. The Atlantic. https://www.theatlantic.com/health/archive/2021/06/novavax-now-best-covid-19-vaccine/619276/

Covid-19 Vaccine Resource Center. (n.d.). Https://Www.Nejm.Org. Retrieved July 19, 2021, from https://www.nejm.org/covid-vaccine